• Visit exhibit 106 to learn how Covalon is leading the charge with compassion driven innovation through gentler infection prevention solutions

MISSISSAUGA, Ontario / May 16, 2023 / Business Wire / Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced it is a silver sponsor of the 2023 Neonatal/Fetal Conference: From the Womb and Beyond being held both virtually and in-person in Columbus, Ohio from May 17 to 19, 2023. Healthcare providers looking for more compassionate care solutions for pediatric patients should visit Covalon at exhibit 106 to learn more about Covalon’s unique position to provide “apology-free” dressings.

“Whether it’s placing an IV-line, checking vitals or administering life-saving treatment, patient care begins with the skin,” said Ron Hebert, Senior Vice President, Marketing, Covalon. “An IV-dressing shouldn’t cause neonates and their caregivers distress, yet many do. In addition to preventing infections, our soft silicone dressings are designed to keep even the most delicate skin safe and protected – no more adhesive removers, no more apologies.”

This year’s Neonatal/Fetal Conference is bringing together practitioners, clinicians, and students in the fields of neonatology, pediatrics, obstetrics, genetic counseling, maternal fetal medicine, fetal surgery, pediatric surgery, cardiology and sonography, to highlight concepts of continuous quality improvement and safety in fetal and neonatal practice by offering science, methodology, practice initiatives and discussion points.

Covalon’s gentle and effective infection prevention and skin protection solutions that are well-suited for pediatric patients include:

• CovaClear^® IV – utilizes soft silicone adhesive technology to help protect patients from skin injuries, but does not incorporate antimicrobials, for use with patients who either don't require or cannot tolerate antimicrobials.
• VALGuard^® - an FDA listed, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
• IV Clear^® - the world’s only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.
• SurgiClear^® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.

Conference details

Dates: Wednesday, May 17, 7:30am – Friday, May 19, 2023, 5pm
Venue: Online and in person at Nationwide Children’s Hospital Conference Center (520 Butterfly Gardens Dr, Columbus, OH, USA). To make an appointment with Covalon’s on-site representatives, please contact Ron Hebert, SVP Marketing, at This email address is being protected from spambots. You need JavaScript enabled to view it.
Registration: https://nationwidechildrens.cloud-cme.com/course/courseoverview?P=0&EID=25625

For healthcare providers who are not able to attend the conference but are interested in learning more about Covalon’s solutions, visit www.covalon.com or follow Covalon on LinkedIn, Facebook, Instagram or Twitter.

About Covalon

Covalon Technologies Ltd. is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, we offer innovative, gentler, and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2022, which is available on the Company’s profile at www.sedar.com, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.